HCPLive

Even Brief Interruptions Dramatically Increase Potential for Medical Errors

 
WEDNESDAY, Jan. 16 (HealthDay News) -- Even momentary interruptions of two to four seconds can significantly affect a person's ability to accurately complete a task requiring considerable thought, according to research published online Jan. 7 in the Journal of Experimental Psychology: General.

Erik M. Altmann, Ph.D., of the Michigan State University in East Lansing, and colleagues studied the effect of short interruptions on the ability of 300 undergraduate students to perform a computer-based sequential task that combined a routine sequencing component with relatively complex individual steps.

The researchers found that long interruptions, averaging about 4.4 seconds, tripled the rate of sequence errors, while interruptions averaging 2.8 seconds doubled the error rate. Interruptions did not have an effect on non-sequence error rates, however, suggesting that interruptions can disrupt a person's ability to maintain their place without disrupting the individual steps themselves.

In conclusion, our core empirical finding is that, when someone is momentarily interrupted or distracted and then returns to their task, they may do so without obvious hesitation, but with an increased chance of resuming at a different point in their train of thought than they might have otherwise," the authors write. "This contextual jitter -- being taken out of the moment and landed back in a slightly different place -- may be why even momentary interruptions can seem jarring when they occur during a cognitively engaging activity."
 

Abstract
Full Text (subscription or payment may be required)


Copyright © 2013 HealthDay. All rights reserved.
 

Most Popular

Recommended Reading

Tenofovir alafenamide, which results in 90% lower circulating plasma tenofovir than standard tenofovir disoproxil fumarate, is associated with similar virologic response rates as the standard regimen, but with an improved safety profile.
Combination treatment with daclatasvir and asunaprevir plus interferon/ribavirin had high success rates in a 24-week clinical trial for treatment of hepatitis C in patients coninfected with HIV.
An interferon/ribavirin-free pill that combines two drugs to treat patients with certain genotypes of hepatitis C who are also infected with HIV was found to be highly effective in a 12-week trial, clearing the hepatitis C virus from almost all the patients involved.
Novel second-generation HIV-1 maturation inhibitor shows favorable antiviral activity and safety profile in HIV-1, subtype B-infected subjects
$vAR$